Sun Pharmaceutical Industries Share Price

pursuing acquisitions. It is now headquartered in Mumbai and operates across the United States, emerging markets, and several other regions.

Its shares are listed on both major Indian exchanges: NSE: SUNPHARMA on the National Stock Exchange and BOM: 524715 on the Bombay Stock Exchange.

Over time, the product mix has widened considerably. What began with a limited portfolio now covers generics, branded generics, speciality medicines, APIs, and over-the-counter products.

Sun Pharma Business Segments and Revenue Model

Operations cover a broad set of therapeutic areas consisting of cardiology, dermatology, psychiatry, neurology, oncology, gastroenterology, ophthalmology, and respiratory care. The product base is aligned with this spread, comprising complex generics, speciality formulations and APIs. These are supplied in multiple formats: tablets, injectables, inhalers, as well as topical treatments.

Revenue mix differs across regions. The United States accounts for the largest share, driven mainly by generics and speciality products. India’s contribution comes from branded formulations. Emerging markets add their share through branded generics.

Revenue does not rely on a single source. Alongside product sales, the company also earns from licensing arrangements, contract manufacturing, and partnerships with other pharmaceutical firms. The speciality segment, dermatology, ophthalmology and oncology in particular, has gradually taken on greater importance within the overall mix.

Sun Pharma Key Milestones

• 1983: Incorporated; initial operations focused on psychiatry in Kolkata
  
• 1991: Set up the first research centre
  
• 1994: Listed on Indian stock exchanges
  
• 1997: First international acquisition - Caraco Pharmaceutical Laboratories
  
• 2007: Research business demerged into SPARC Ltd.
  
• 2010: Acquisition of Taro Pharmaceutical Industries
  
• 2014: Acquisition of Ranbaxy
  
• 2018: Launch of ILUMYA
  
• 2023: Acquisition of Concert Pharmaceuticals
  
• 2025: Acquisition of Checkpoint Therapeutics
  

Sun Pharma ESG and Sustainability

• There are ongoing investments in compliance systems and quality standards across facilities.
  
• CSR programmes cover healthcare, education, and community initiatives.
  
• Launched the Malaria Elimination Demonstration Project (MEDP) to curb indigenous malaria cases across rural India.
  
• Installed Mobile Healthcare Units (MHUs) to deliver primary healthcare services to over 5,65,000 people located around areas close to our manufacturing plants and other establishments.
  
• Established the Sun Pharma Science Foundation to promote scientific endeavours in India.
  
• Governance practices are aligned with global regulatory expectations.
  
• Improving access to medicines remains an ongoing priority.
  

Sun Pharma Awards and Recognitions

• Recognised amongst the top 5% of global pharmaceutical companies in S&P Global Sustainability Yearbook 2025
  
• Recognised for its presence in the US generics and speciality segments
  
• Won the Dun & Bradstreet India Corporate Award under the Sectoral Performance-based category- Pharmaceuticals (2021)
  
• Ranked #1 generic pharmaceutical company by PatientView (2021)
  
• Awarded the Golden Peacock Award for Corporate Social Responsibility (2020)
  
• Received the DIANA (Distribution Industry Award for Notable Achievements in Healthcare) award for ‘Best New Product Introduction/Promotion’ (2021)
  
• Ranked No. 1 in the pharma sector and No. 16 overall in the BW Businessworld list of India’s Most Respected Companies (2019)
  
• Listed among the Forbes World’s Best Regarded companies
  
• Received the India Pharma Research Development Award 2015 from the Ministry of Chemicals & Fertilisers, Government of India